APO Research
Talk to an analyst

APO RESEARCH · REPORT

Generic Injectables

Generic injectables refer to sterile solutions (including emulsions and suspensions) made of drugs for injection into the body, and sterile powders or concentrated solutions that are prepared into solutions or suspensions before use.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Generic injectables refer to sterile solutions (including emulsions and suspensions) made of drugs for injection into the body, and sterile powders or concentrated solutions that are prepared into solutions or suspensions before use.

The injection is fast and reliable, not affected by pH, enzymes, food, etc., has no first-pass effect, and can play a systemic or local positioning effect. It is suitable for patients who are not suitable for oral medicine and patients who cannot be taken orally. However, the development and production process of injections is complicated and safe. The body has poor adaptability and high cost.

Selected research

Market Outlook & Growth Opportunities

Global Generic Injectables Market Outlook and Growth Opportunities 2026

28 December 2025191 pages

Choose your research edition.

Industry ResearchGeneric Injectables Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Generic Injectables Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Generic Injectables Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Generic Injectables Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Generic Injectables Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

Generic injectables refer to sterile solutions (including emulsions and suspensions) made of drugs for injection into the body, and sterile powders or concentrated solutions that are prepared into solutions or suspensions before use.

The injection is fast and reliable, not affected by pH, enzymes, food, etc., has no first-pass effect, and can play a systemic or local positioning effect. It is suitable for patients who are not suitable for oral medicine and patients who cannot be taken orally. However, the development and production process of injections is complicated and safe. The body has poor adaptability and high cost.

In the segment of generic sterile injectables, the Hospira (Pfizer Inc.) is the largest player, and Fresenius Kabi is the second. Top two players hold a share about 27% in 2019. The US market is dominated by two players like Hospira (Pfizer Inc.), Fresenius Kabi, Sandoz (Novartis), Hikma Pharmaceuticals PLC, Dr. Reddy’s Laboratories Ltd, Grifols, Nichi-Iko Group (Sagent), Teva Pharmaceutical, Auromedics, Sanofi, Gland Pharma and Endo International PLC.

Read the full market overview

This report provides an overview of the global Generic Injectables market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Generic Injectables and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Generic Injectables revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Generic Injectables market.

Generic Injectables Segment by Company

Hospira (Pfizer Inc.)

Fresenius Kabi

Sandoz (Novartis)

Hikma Pharmaceuticals PLC

Dr. Reddy’s Laboratories Ltd

Grifols

Nichi-Iko Group (Sagent)

Teva Pharmaceutical

Auromedics

Sanofi

Gland Pharma

Endo International PLC

Generic Injectables Segment by Type

Small Molecule

Large Molecule

Generic Injectables Segment by Application

Oncology

Anesthesia

Anti-Infectives

Parenteral Nutrition

Cardiovascular Diseases

Generic Injectables Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Generic Injectables status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Generic Injectables key companies, revenue, market share, and recent developments.

3. To split the Generic Injectables breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Generic Injectables market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Generic Injectables significant trends, drivers, influence factors in global and regions.

6. To analyze Generic Injectables competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Generic Injectables market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Generic Injectables and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Generic Injectables.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Generic Injectables industry.

Chapter 3: Detailed analysis of Generic Injectables company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Generic Injectables in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Generic Injectables in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Generic Injectables Industry Trends Table 2. Generic Injectables Industry Drivers Table 3. Generic Injectables Industry Opportunities and Challenges Table 4. Generic Injectables Industry Restraints Table 5. Global Generic Injectables Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Generic Injectables Revenue Share by Company (2021-2026) Table 7. Global Generic Injectables Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Generic Injectables Key Company Manufacturing Base & Headquarters Table 9. Global Generic Injectables Company, Product Type & Application Table 10. Global Generic Injectables Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Generic Injectables by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Small Molecule Table 15. Significant Companies of Large Molecule Table 16. Global Generic Injectables Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Generic Injectables Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Generic Injectables Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Generic Injectables Sales Value Share by Type (2021-2026) Table 20. Global Generic Injectables Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Oncology Table 22. Significant Companies of Anesthesia Table 23. Significant Companies of Anti-Infectives Table 24. Significant Companies of Parenteral Nutrition Table 25. Significant Companies of Cardiovascular Diseases Table 26. Global Generic Injectables Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Generic Injectables Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Generic Injectables Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Generic Injectables Sales Value Share by Application (2021-2026) Table 30. Global Generic Injectables Sales Value Share by Application (2027-2032) Table 31. Global Generic Injectables Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Generic Injectables Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Generic Injectables Sales Value Share by Region (2021-2026) Table 34. Global Generic Injectables Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Generic Injectables Sales Value Share by Region (2027-2032) Table 36. Global Generic Injectables Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Generic Injectables Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Generic Injectables Sales Value Market Share by Country (2021-2026) Table 39. Global Generic Injectables Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Generic Injectables Sales Value Market Share by Country (2027-2032) Table 41. Hospira (Pfizer Inc.) Company Information Table 42. Hospira (Pfizer Inc.) Business Overview Table 43. Hospira (Pfizer Inc.) Generic Injectables Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Hospira (Pfizer Inc.) Generic Injectables Product Portfolio Table 45. Hospira (Pfizer Inc.) Recent Development Table 46. Fresenius Kabi Company Information Table 47. Fresenius Kabi Business Overview Table 48. Fresenius Kabi Generic Injectables Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Fresenius Kabi Generic Injectables Product Portfolio Table 50. Fresenius Kabi Recent Development Table 51. Sandoz (Novartis) Company Information Table 52. Sandoz (Novartis) Business Overview Table 53. Sandoz (Novartis) Generic Injectables Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Sandoz (Novartis) Generic Injectables Product Portfolio Table 55. Sandoz (Novartis) Recent Development Table 56. Hikma Pharmaceuticals PLC Company Information Table 57. Hikma Pharmaceuticals PLC Business Overview Table 58. Hikma Pharmaceuticals PLC Generic Injectables Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Hikma Pharmaceuticals PLC Generic Injectables Product Portfolio Table 60. Hikma Pharmaceuticals PLC Recent Development Table 61. Dr. Reddy’s Laboratories Ltd Company Information Table 62. Dr. Reddy’s Laboratories Ltd Business Overview Table 63. Dr. Reddy’s Laboratories Ltd Generic Injectables Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Dr. Reddy’s Laboratories Ltd Generic Injectables Product Portfolio Table 65. Dr. Reddy’s Laboratories Ltd Recent Development Table 66. Grifols Company Information Table 67. Grifols Business Overview Table 68. Grifols Generic Injectables Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Grifols Generic Injectables Product Portfolio Table 70. Grifols Recent Development Table 71. Nichi-Iko Group (Sagent) Company Information Table 72. Nichi-Iko Group (Sagent) Business Overview Table 73. Nichi-Iko Group (Sagent) Generic Injectables Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Nichi-Iko Group (Sagent) Generic Injectables Product Portfolio Table 75. Nichi-Iko Group (Sagent) Recent Development Table 76. Teva Pharmaceutical Company Information Table 77. Teva Pharmaceutical Business Overview Table 78. Teva Pharmaceutical Generic Injectables Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Teva Pharmaceutical Generic Injectables Product Portfolio Table 80. Teva Pharmaceutical Recent Development Table 81. Auromedics Company Information Table 82. Auromedics Business Overview Table 83. Auromedics Generic Injectables Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Auromedics Generic Injectables Product Portfolio Table 85. Auromedics Recent Development Table 86. Sanofi Company Information Table 87. Sanofi Business Overview Table 88. Sanofi Generic Injectables Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Sanofi Generic Injectables Product Portfolio Table 90. Sanofi Recent Development Table 91. Gland Pharma Company Information Table 92. Gland Pharma Business Overview Table 93. Gland Pharma Generic Injectables Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Gland Pharma Generic Injectables Product Portfolio Table 95. Gland Pharma Recent Development Table 96. Endo International PLC Company Information Table 97. Endo International PLC Business Overview Table 98. Endo International PLC Generic Injectables Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Endo International PLC Generic Injectables Product Portfolio Table 100. Endo International PLC Recent Development Table 101. Research Programs/Design for This Report Table 102. Authors List of This Report Table 103. Secondary Sources Table 104. Primary Sources List of Figures Figure 1. Generic Injectables Product Image Figure 2. Global Generic Injectables Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Generic Injectables Market Size (2021-2032) & (US$ Million) Figure 4. Global Generic Injectables Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Small Molecule Image Figure 8. Large Molecule Image Figure 9. Global Generic Injectables Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Generic Injectables Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Generic Injectables Sales Value Share by Type (2021-2032) Figure 12. Oncology Image Figure 13. Anesthesia Image Figure 14. Anti-Infectives Image Figure 15. Parenteral Nutrition Image Figure 16. Cardiovascular Diseases Image Figure 17. Global Generic Injectables Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Generic Injectables Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Generic Injectables Sales Value Share by Application (2021-2032) Figure 20. Global Generic Injectables Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Generic Injectables Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Generic Injectables Sales Value (2021-2032) & (US$ Million) Figure 23. North America Generic Injectables Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Generic Injectables Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Generic Injectables Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Generic Injectables Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Generic Injectables Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Generic Injectables Sales Value (2021-2032) & (US$ Million) Figure 29. South America Generic Injectables Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Generic Injectables Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Generic Injectables Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Generic Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Generic Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Generic Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Generic Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Generic Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Generic Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Generic Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Generic Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Generic Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Generic Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Generic Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Generic Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Generic Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Generic Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Generic Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Generic Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Generic Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Generic Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Generic Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Generic Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Generic Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Generic Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Generic Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Generic Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Generic Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Generic Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Generic Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Generic Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Generic Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Generic Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Generic Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Generic Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Generic Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Generic Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Generic Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Generic Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Generic Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Generic Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Generic Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Generic Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Generic Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Generic Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Generic Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Generic Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Generic Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Generic Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Generic Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Generic Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Generic Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Generic Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Generic Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Generic Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Generic Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Generic Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Generic Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Generic Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Generic Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Generic Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Generic Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Generic Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Generic Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Generic Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Generic Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Generic Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Generic Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Generic Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Generic Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Generic Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Generic Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Generic Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Generic Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Generic Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Generic Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Generic Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Generic Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Generic Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Generic Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Generic Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Generic Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Generic Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Generic Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Generic Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Generic Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Generic Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Small Molecule
  • Large Molecule
Applications
  • Oncology
  • Anesthesia
  • Anti-Infectives
  • Parenteral Nutrition
  • Cardiovascular Diseases
Companies covered
  • Hospira (Pfizer Inc.)
  • Fresenius Kabi
  • Sandoz (Novartis)
  • Hikma Pharmaceuticals PLC
  • Dr. Reddy’s Laboratories Ltd
  • Grifols
  • Nichi-Iko Group (Sagent)
  • Teva Pharmaceutical
  • Auromedics
  • Sanofi
  • Gland Pharma
  • Endo International PLC

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Generic Injectables Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Generic Injectables Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Generic Injectables Market Dynamics
  1. 2.1 Generic Injectables Industry Trends
  2. 2.2 Generic Injectables Industry Drivers
  3. 2.3 Generic Injectables Industry Opportunities and Challenges
  4. 2.4 Generic Injectables Industry Restraints
3 Generic Injectables Market by Company
  1. 3.1 Global Generic Injectables Company Revenue Ranking in 2025
  2. 3.2 Global Generic Injectables Revenue by Company (2021-2026)
  3. 3.3 Global Generic Injectables Company Ranking (2024-2026)
  4. 3.4 Global Generic Injectables Company Manufacturing Base and Headquarters
  5. 3.5 Global Generic Injectables Company Product Type and Application
  6. 3.6 Global Generic Injectables Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Generic Injectables Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Generic Injectables Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Generic Injectables Market by Type
  1. 4.1 Generic Injectables Type Introduction
  2. 4.1.1 Small Molecule
  3. 4.1.2 Large Molecule
  4. 4.2 Global Generic Injectables Sales Value by Type
  5. 4.2.1 Global Generic Injectables Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Generic Injectables Sales Value by Type (2021-2032)
  7. 4.2.3 Global Generic Injectables Sales Value Share by Type (2021-2032)
5 Generic Injectables Market by Application
  1. 5.1 Generic Injectables Application Introduction
  2. 5.1.1 Oncology
  3. 5.1.2 Anesthesia
  4. 5.1.3 Anti-Infectives
  5. 5.1.4 Parenteral Nutrition
  6. 5.1.5 Cardiovascular Diseases
  7. 5.2 Global Generic Injectables Sales Value by Application
  8. 5.2.1 Global Generic Injectables Sales Value by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Generic Injectables Sales Value by Application (2021-2032)
  10. 5.2.3 Global Generic Injectables Sales Value Share by Application (2021-2032)
6 Generic Injectables Regional Value Analysis
  1. 6.1 Global Generic Injectables Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Generic Injectables Sales Value by Region (2021-2032)
  3. 6.2.1 Global Generic Injectables Sales Value by Region: 2021-2026
  4. 6.2.2 Global Generic Injectables Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Generic Injectables Sales Value (2021-2032)
  7. 6.3.2 North America Generic Injectables Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Generic Injectables Sales Value (2021-2032)
  10. 6.4.2 Europe Generic Injectables Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Generic Injectables Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Generic Injectables Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Generic Injectables Sales Value (2021-2032)
  16. 6.6.2 South America Generic Injectables Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Generic Injectables Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Generic Injectables Sales Value Share by Country, 2025 VS 2032
7 Generic Injectables Country-level Value Analysis
  1. 7.1 Global Generic Injectables Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Generic Injectables Sales Value by Country (2021-2032)
  3. 7.2.1 Global Generic Injectables Sales Value by Country (2021-2026)
  4. 7.2.2 Global Generic Injectables Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Generic Injectables Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Generic Injectables Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Generic Injectables Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Generic Injectables Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Generic Injectables Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Generic Injectables Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Generic Injectables Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Generic Injectables Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Generic Injectables Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Generic Injectables Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Generic Injectables Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Generic Injectables Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Generic Injectables Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Generic Injectables Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Generic Injectables Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Generic Injectables Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Generic Injectables Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Generic Injectables Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Generic Injectables Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Generic Injectables Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Generic Injectables Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Generic Injectables Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Generic Injectables Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Generic Injectables Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Generic Injectables Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Generic Injectables Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Generic Injectables Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Generic Injectables Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Generic Injectables Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Generic Injectables Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Generic Injectables Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Generic Injectables Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Generic Injectables Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Generic Injectables Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Generic Injectables Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Generic Injectables Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Generic Injectables Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Generic Injectables Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Generic Injectables Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Generic Injectables Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Generic Injectables Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Generic Injectables Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Generic Injectables Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Generic Injectables Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Generic Injectables Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Generic Injectables Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Generic Injectables Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Generic Injectables Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Generic Injectables Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Generic Injectables Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Generic Injectables Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Generic Injectables Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Generic Injectables Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Generic Injectables Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Generic Injectables Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Generic Injectables Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Generic Injectables Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Generic Injectables Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Generic Injectables Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Generic Injectables Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Generic Injectables Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Generic Injectables Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Generic Injectables Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Generic Injectables Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Generic Injectables Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Generic Injectables Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Generic Injectables Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Generic Injectables Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Generic Injectables Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Generic Injectables Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Generic Injectables Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Generic Injectables Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Generic Injectables Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Generic Injectables Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Generic Injectables Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Generic Injectables Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Generic Injectables Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Generic Injectables Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Generic Injectables Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Generic Injectables Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Generic Injectables Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Generic Injectables Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Generic Injectables Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Generic Injectables Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Hospira (Pfizer Inc.)
  2. 8.1.1 Hospira (Pfizer Inc.) Company Information
  3. 8.1.2 Hospira (Pfizer Inc.) Business Overview
  4. 8.1.3 Hospira (Pfizer Inc.) Generic Injectables Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Hospira (Pfizer Inc.) Generic Injectables Product Portfolio
  6. 8.1.5 Hospira (Pfizer Inc.) Recent Developments
  7. 8.2 Fresenius Kabi
  8. 8.2.1 Fresenius Kabi Company Information
  9. 8.2.2 Fresenius Kabi Business Overview
  10. 8.2.3 Fresenius Kabi Generic Injectables Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Fresenius Kabi Generic Injectables Product Portfolio
  12. 8.2.5 Fresenius Kabi Recent Developments
  13. 8.3 Sandoz (Novartis)
  14. 8.3.1 Sandoz (Novartis) Company Information
  15. 8.3.2 Sandoz (Novartis) Business Overview
  16. 8.3.3 Sandoz (Novartis) Generic Injectables Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Sandoz (Novartis) Generic Injectables Product Portfolio
  18. 8.3.5 Sandoz (Novartis) Recent Developments
  19. 8.4 Hikma Pharmaceuticals PLC
  20. 8.4.1 Hikma Pharmaceuticals PLC Company Information
  21. 8.4.2 Hikma Pharmaceuticals PLC Business Overview
  22. 8.4.3 Hikma Pharmaceuticals PLC Generic Injectables Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Hikma Pharmaceuticals PLC Generic Injectables Product Portfolio
  24. 8.4.5 Hikma Pharmaceuticals PLC Recent Developments
  25. 8.5 Dr. Reddy’s Laboratories Ltd
  26. 8.5.1 Dr. Reddy’s Laboratories Ltd Company Information
  27. 8.5.2 Dr. Reddy’s Laboratories Ltd Business Overview
  28. 8.5.3 Dr. Reddy’s Laboratories Ltd Generic Injectables Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Dr. Reddy’s Laboratories Ltd Generic Injectables Product Portfolio
  30. 8.5.5 Dr. Reddy’s Laboratories Ltd Recent Developments
  31. 8.6 Grifols
  32. 8.6.1 Grifols Company Information
  33. 8.6.2 Grifols Business Overview
  34. 8.6.3 Grifols Generic Injectables Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Grifols Generic Injectables Product Portfolio
  36. 8.6.5 Grifols Recent Developments
  37. 8.7 Nichi-Iko Group (Sagent)
  38. 8.7.1 Nichi-Iko Group (Sagent) Company Information
  39. 8.7.2 Nichi-Iko Group (Sagent) Business Overview
  40. 8.7.3 Nichi-Iko Group (Sagent) Generic Injectables Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Nichi-Iko Group (Sagent) Generic Injectables Product Portfolio
  42. 8.7.5 Nichi-Iko Group (Sagent) Recent Developments
  43. 8.8 Teva Pharmaceutical
  44. 8.8.1 Teva Pharmaceutical Company Information
  45. 8.8.2 Teva Pharmaceutical Business Overview
  46. 8.8.3 Teva Pharmaceutical Generic Injectables Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Teva Pharmaceutical Generic Injectables Product Portfolio
  48. 8.8.5 Teva Pharmaceutical Recent Developments
  49. 8.9 Auromedics
  50. 8.9.1 Auromedics Company Information
  51. 8.9.2 Auromedics Business Overview
  52. 8.9.3 Auromedics Generic Injectables Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Auromedics Generic Injectables Product Portfolio
  54. 8.9.5 Auromedics Recent Developments
  55. 8.10 Sanofi
  56. 8.10.1 Sanofi Company Information
  57. 8.10.2 Sanofi Business Overview
  58. 8.10.3 Sanofi Generic Injectables Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Sanofi Generic Injectables Product Portfolio
  60. 8.10.5 Sanofi Recent Developments
  61. 8.11 Gland Pharma
  62. 8.11.1 Gland Pharma Company Information
  63. 8.11.2 Gland Pharma Business Overview
  64. 8.11.3 Gland Pharma Generic Injectables Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Gland Pharma Generic Injectables Product Portfolio
  66. 8.11.5 Gland Pharma Recent Developments
  67. 8.12 Endo International PLC
  68. 8.12.1 Endo International PLC Company Information
  69. 8.12.2 Endo International PLC Business Overview
  70. 8.12.3 Endo International PLC Generic Injectables Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Endo International PLC Generic Injectables Product Portfolio
  72. 8.12.5 Endo International PLC Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst